Low breast cancer recurrence rates confirmed 10 years after tailored nodal-response radiotherapy.
This study with 10-year follow-up confirmed that radiotherapy tailored to pathological nodal response (rather than standardized protocols) in breast cancer achieves very low locoregional recurrence rates—less than 3% of patients experienced recurrence, most within the first 5 years.
Low breast cancer recurrence rates confirmed 10 years after tailored nodal-response radiotherapy.
This study with 10-year follow-up confirmed that radiotherapy tailored to pathological nodal response (rather than standardized protocols) in breast cancer achieves very low locoregional recurrence rates—less than 3% of patients experienced recurrence, most within the first 5 years.
The finding supports the safety and long-term durability of response-guided radiotherapy de-escalation strategies in breast cancer. De-escalating treatment intensity for patients who respond well to neoadjuvant therapy without compromising local control is a major research goal.
This 10-year data provides important long-term reassurance for this approach.
Key Findings
- Less than 3% locoregional recurrence rate at 10 years after tailored nodal-response RT
- Most recurrences occurred in the first 5 years
- Tailored radiotherapy based on pathological nodal response is durable long-term
- Results support de-escalation strategies in responding breast cancer patients
- 10-year follow-up from EBCC meeting presentation
Implications
10-year low recurrence rates support adopting nodal-response-tailored radiotherapy as a standard option. This allows appropriate patients to receive less extensive radiation while maintaining excellent tumor control.
Caveats
Meeting abstract; limited methodological detail; abstract-only. Patient selection criteria for tailored RT may limit generalizability. Specific de-escalation protocol details not provided in this summary.
Source: MedPage Hematology/Oncology — 2026-03-30
